Actively Recruiting
Phase 2 Study of Electrochemotherapy Using Bleomycin for Treating Women With Recurrent Vulvar Cancer
Led by Institute of Oncology Ljubljana · Updated on 2026-03-02
13
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating electrochemotherapy ECT as a neoadjuvant treatment for women with local recurrence of vulvar cancer in this phase III interventional study. ECT combines intravenous bleomycin with electric pulses to increase drug uptake into tumor cells. The study aims to assess tumor response, reduce the need for disfiguring surgery, and improve quality of life. Treatment outcomes will be assessed using RECIST criteria while adverse events will be recorded with CTCAE version 5.0. Participants receive ECT following ESOPE standard operating procedures, involving intravenous bleomycin administration followed by electric pulses delivered to the tumor area and surrounding safety margin. The study compares outcomes of ECT-treated patients with a matched control group previously treated surgically. The planned duration of the study is five years, enrolling about 20 women aged 18 or older. During the study, participants will be monitored for tumor response, adverse events, pain levels using a visual analog scale diary, and quality of life via the EQ-5D questionnaire. Follow-up visits will continue up to five years to collect data on these measures, including length of hospital stay. Safety and treatment effects will be carefully tracked from treatment until 30 days after ECT, with ongoing quality of life assessments during the follow-up period.
CONDITIONS
Brief Title
Electrochemotherapy for Recurrent Vulvar Cancer
Research Team
S
Sebastjan Merlo, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here